---
$id: https://graph.org.ai/products/commodity/51131732
$type: Product
source: UNSPSC
code: "51131732"
title: "Modipafant"
class: "51131700"
classTitle: "Thrombolytic drugs and platelet aggregation inhibitors"
family: "51130000"
familyTitle: "Hematolic drugs"
segment: "51000000"
segmentTitle: "Pharmaceutical Products incl. Contraceptives and Vaccines"


---

# Modipafant

**UNSPSC Code**: 51131732
**Class**: [Thrombolytic drugs and platelet aggregation inhibitors](Thrombolytic drugs and platelet aggregation inhibitors.mdx)
**Family**: [Hematolic drugs](../Hematolic drugs.mdx)
**Segment**: [Pharmaceutical Products incl. Contraceptives and Vaccines](../../Pharmaceutical Products incl. Contraceptives and Vaccines.mdx)

This classification denotes an antiplatelet agent with the molecular formula C34H29ClN6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1DMI0E5023, chemically known as ethyl ( )-(r)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-2-(p-(2-methyl-1h-imidazo(4,5-c)pyridin-1-yl)phenyl)-5-(2-pyridylcarbamoyl)nicotinate. but generally known as modipafant, which bears US NIH Compound Identifier 3047770. European Medicines Agency schedules Modipafant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09029MIG. The term MODIPAFANT is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). Most nations schedule modipafant under HS 29333999 and SITC 51574. As of Q4 2014, MODIPAFANT remains the US FDA Preferred Term for this commodity. Modipafant bears US NLM identifiers UMLS ID C0287533 and NCI Concept Code C90752. SMILES: CLC1C(C2C(=C(NC(=C2C(=O)NC2NCCCC2)C)C2CCC(N3C4C(NC3C)CNCC4)CC2)C(=O)OCC)CCCC1.

